Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leflunomide in clinical practice.

Patrícia Pinto1, Maxime Dougados

  • 1René Descartes University, Medicine Faculty, France. patriciaapinto@iol.pt

Acta Reumatologica Portuguesa
|November 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Annals of the rheumatic diseases·2019
Same author

Self-reported competencies and educational needs of rheumatology nurses: Results of a national survey.

Joint bone spine·2019
Same author

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients.

RMD open·2019
Same author

Evaluation of the performances of 'typical' imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study.

RMD open·2019
Same author

Novel DMARD monotherapy in rheumatoid arthritis.

Lancet (London, England)·2019
Same author

Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort.

Arthritis research & therapy·2019
Same journal

The relevance of a multidisciplinary care in the management of patients with Osteogenesis Imperfecta.

Acta reumatologica portuguesa·2021
Same journal

The Role of Medical Therapy in Refractory Pigmented Villonodular Synovitis.

Acta reumatologica portuguesa·2021
Same journal

Urticariform reaction lupus-like induced by adalimumab: a rare adverse effect.

Acta reumatologica portuguesa·2021
Same journal

Abdominal pain in Systemic Lupus Erythematosus: About a rare cause.

Acta reumatologica portuguesa·2021
Same journal

Clinical images of ENT involvement in ANCA associated Vasculitis.

Acta reumatologica portuguesa·2021
Same journal

Bone marrow edema syndrome: an unusual cause for spontaneous unrelentless bilateral knee pain.

Acta reumatologica portuguesa·2021
See all related articles

Leflunomide, an active metabolite, inhibits pyrimidine synthesis and is effective for rheumatoid arthritis. This review explores its clinical use and potential beyond rheumatoid arthritis.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Leflunomide (LEF) is a prodrug converted to its active metabolite, A77 1726.
  • A77 1726 inhibits de novo pyrimidine nucleotide biosynthesis via dihydroorotate dehydrogenase (DHODH).
  • LEF is a disease-modifying antirheumatic drug (DMARD) with proven efficacy and safety in rheumatoid arthritis (RA).

Purpose of the Study:

  • To review the current clinical applications of Leflunomide.
  • To explore potential uses of LEF beyond its approved indication for rheumatoid arthritis.

Main Methods:

  • Literature review of studies on Leflunomide's efficacy, safety, and mechanism of action.
  • Analysis of LEF's use in various autoimmune conditions.

Main Results:

Related Experiment Videos

  • LEF demonstrates efficacy in managing rheumatoid arthritis, including limiting radiological progression.
  • LEF has shown utility in other autoimmune diseases such as Psoriatic Arthritis, Wegener granulomatosis, Systemic Lupus Erythematosus, and Sarcoidosis.

    • Conclusions:

    • Leflunomide is an established treatment for rheumatoid arthritis.
    • Further investigation into LEF's broader therapeutic potential in autoimmune diseases is warranted.